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Abstract  5 
 6 
Context 7 
Certain treatments are potentially inappropriate when administered to nursing homes residents at the end 8 
of life and should be carefully considered. An international comparison of potentially inappropriate 9 
treatments allows insight into common issues and country-specific challenges of end-of-life care in nursing 10 
homes and helps direct health care policy in this area.   11 
 12 
Objectives 13 
To estimate the prevalence of potentially inappropriate treatments in the last week of life in nursing home 14 
residents, and analyze the differences in prevalence between countries. 15 
 16 
Methods 17 
A cross-sectional study of deceased residents in nursing homes (2015) in six European countries: Belgium 18 
(Flanders), England, Finland, Italy, the Netherlands and Poland. Potentially inappropriate treatments 19 
included: enteral administration of nutrition, parental administration of nutrition, artificial fluids, 20 
resuscitation, artificial ventilation, blood transfusion, chemotherapy/radiotherapy, dialysis, surgery, 21 
antibiotics, statins, antidiabetics, new oral anticoagulants. Nurses were questioned about whether these 22 
treatments were administered in the last week of life. 23 
 24 
Results 25 
We included 1,384 deceased residents from 322 nursing homes. In most countries, potentially 26 
inappropriate treatments were rarely used, with a maximum of 18.3% of residents receiving at least one 27 
treatment in Poland. Exceptions were antibiotics in all countries (between 11.3% in Belgium and 45% in 28 




Although the prevalence of potentially inappropriate treatments in the last week of life was generally low, 33 
antibiotics were frequently prescribed in all countries. In Poland and Italy, the prevalence of artificial 34 
 2 
administration of food/fluids in the last week of life was high, possibly reflecting country differences in 35 
legislation, care organization and culture, and the palliative care competences of staff. 36 
 37 
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Key message: 41 
Potentially inappropriate treatments in the last week of life of nursing homes residents are uncommon in 42 
most countries except for the use of antibiotics. In Italy and Poland these treatments are more prevalent, 43 
especially artificial nutrition and fluid treatments and antibiotics, possibly due to country differences in 44 
legislation, organization, culture and staff competence.  45 
 46 






























Introduction     76 
 77 
In Europe, an increasing number of older people spend their last months in nursing homes and up 78 
to 38% of people over 65 years die there(1). We conducted the PACE (Palliative Care for Older 79 
People) cross-sectional study in nursing homes in Belgium, England, Finland, Italy, the Netherlands 80 
and Poland(2), and demonstrated that residents in these countries die at a mean age of 85 years, 81 
often with advanced dementia, multiple comorbidities and clinical complications(1,3,4). This 82 
makes them a particularly vulnerable population for whom providing appropriate treatments at 83 
the end of life is crucial, albeit challenging(1,3–8).The difficulty of predicting death in older people 84 
complicates the decision on whether a treatment or medication is still appropriate(9); staff are 85 
sometimes too optimistic about the benefits of such treatments(10,11), and residents are often 86 
poorly informed of the possible complications(12).  87 
 88 
Recent studies show that certain treatments are potentially inappropriate when administered to 89 
older people at the end of life, in particular those with dementia and those living in nursing homes, 90 
and should therefore be carefully considered(13–15). Antibiotics and medications like anti-91 
diabetics, statins or oral anticoagulants have no or questionable benefit in short-term use in the 92 
last week of life(13). In long-term use, polypharmacy, comorbidities and age-related alterations in 93 
drug metabolism can result in side-effects that cause functional and cognitive impairment in older 94 
adults(16–18). Artificial nutrition and hydration(19–21), resuscitation(22,23) and artificial 95 
ventilation(24–26) can have deleterious effects on quality of life when used in the last week and 96 
can complicate the dying process while blood transfusion, chemo/radiotherapy, dialysis or surgery 97 
can be futile and burdensome with low survival rates and resulting in poor quality of life(10–12,14).  98 
Earlier studies on potentially inappropriate treatments are limited to describing prevalence in one 99 
country or comparison between countries in specific settings such as home care(27) or during the 100 
last month of life(28). So far, there are no studies that have compared prevalence of potentially 101 
inappropriate treatments in the last week of life between European countries. An international 102 
comparison would allow deeper insight into common issues and country-specific challenges in 103 
nursing homes and could help direct health care policy and decision-makers. The aim of the current 104 
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study was to estimate the prevalence of potentially inappropriate treatments in the last week of 105 
life in nursing home residents in six European countries and to study the differences in prevalence 106 
of these treatments between countries. 107 
Methods 108 
Study design and sampling 109 
A cross-sectional study of deceased residents in nursing homes was conducted in 2015 in six 110 
European countries: Belgium (Flanders), England, Finland, Italy, the Netherlands and Poland(2), 111 
using proportional stratified random sampling.  In each country, nursing homes were stratified by 112 
region (provinces or other large regions), by type and by bed capacity (above/below country 113 
median), and sampled randomly to cover the entire country. For each one that declined 114 
participation, another from the same stratum was sampled. Available national (or regional in 115 
Belgium) lists were used for recruitment. In England, we also used the ENRICH (Enabling Research 116 
in Care Homes) network(29). In Italy, a previously created cluster interested in research was used 117 
as the basis for the sample since no national list was available. We aimed to include at least 48 118 
nursing homes per country, to identify a minimum of 192 residents per country or 1,152 in total(2). 119 
The PACE protocol provides more details(2). 120 
 121 
Setting and participants 122 
The term nursing home in this paper refers to ‘collective institutional settings where care, on-site 123 
provision of personal assistance with activities of daily living, and on-site or off-site provision of 124 
nursing and medical care, is provided for older people who live there, 24 hours a day, seven days 125 
a week, for an undefined period of time’ (30). Participating nursing homes reported on all deceased 126 
residents over the preceding three months. Questionnaires on each were sent to the nurse/care 127 
assistant most involved in their care, the manager, and the resident’s general practitioner (GP); the 128 
manager was asked to fill in a questionnaire about the nursing home. 129 
Data collection 130 
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Nursing homes received a letter presenting the PACE project and a call for participation. Further 131 
contact was made via phone or email. The manager nominated an internal contact who provided 132 
an overview of all deceased residents in the preceding three months and a list of the key 133 
respondents for each (staff member, i.e. nurse/care assistant most involved in care, 134 
manager/administrator, GP); these received a paper questionnaire with an anonymous code and 135 
an attached document that guaranteed full anonymity and confidentiality with questionnaires 136 
returned directly to the researchers who monitored them using excel files. In case of non-response, 137 
up to two reminders were sent after three and six weeks.  138 
Measurements 139 
Questionnaires from all three key respondents were used to report on the characteristics of the 140 
resident: age, gender, length of stay in the nursing home, place of death, presence and stage of 141 
dementia at time of death, diseases at time of death and functional and cognitive status during last 142 
month of life (Table 1). Presence of dementia was based on the estimation of the GP, nurse or 143 
both; stage was based on the Global Deterioration Scale and the Cognitive Performance Scale, as 144 
estimated by nursing staff(3) with CPS scores of 5-6 and GDS stage 7 considered as advanced 145 
dementia. The score for functional and cognitive status during last month of life was computed 146 
with the Bedford Alzheimer Nursing Severity Scale (BANS-S)(31), ranging between 7 and 28. Higher 147 
scores indicated greater severity. 148 
In this study, we refer to inappropriate treatments as treatments and/or medication for which ‘the 149 
negative consequences (such as mortality and symptom burden) outweigh the expected health 150 
benefits (such as increased life expectancy or pain relief)’(32). We first performed an extensive 151 
literature search. Next, during multiple meetings with the PACE consortium (i.e. geriatricians, 152 
nurses, psychologists) and palliative care researchers, we  discussed the list of potentially 153 
inappropriate treatments and made a final selection based on the following criteria: 1) used as a 154 
standard treatment for older people, 2) considered potentially life-prolonging, and 3) can be easily 155 
recalled by a nurse filling in the questionnaire. The final selection agreed by the consortium 156 
partners, was: artificial enteral administration of nutrition (e.g. tube feeding, percutaneous 157 
endoscopic gastrostomy i.e. PEG), parenteral administration of nutrition, artificial fluids, 158 
resuscitation, artificial ventilation, blood transfusion, chemotherapy/radiotherapy, dialysis, 159 
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surgery, antibiotics, statins, antidiabetics, new oral anticoagulant (33–38). Nurses were asked 160 
whether, to their knowledge, these were administered in the last week of life or not (meaning 161 
either ‘not at all’ or ‘in the last month except the last week’). The treatments were then subdivided 162 
into five categories: artificial nutrition and hydration treatments (enteral administration nutrition, 163 
parental administration nutrition, artificial fluid), critical treatments (resuscitation and artificial 164 
ventilation), antimicrobial treatments (antibiotics), medications (statins, antidiabetics, new oral 165 
anticoagulants) and other (blood transfusion, chemotherapy/radiotherapy, dialysis, surgery).  166 
 167 
Statistical analysis 168 
Analyses were conducted for deceased residents for whom an assessment by the nurse was made 169 
retrospectively, using IBM SPSS version 25(39). To investigate the effect of missing data (up to 24% 170 
missing values for some treatments), sensitivity analyses were conducted via imputation of 171 
incomplete cases with fully conditional specification (shown in Results and Table 2) and complete 172 
cases (Table 1A in Appendix). The imputation method estimates each missing value based on 173 
associations with other covariates from the dataset using regression analysis (age of resident, 174 
gender of resident, availability and number of visits by GP, comorbidity and cause and place of 175 
death). Demographic and clinical characteristics are reported as mean and standard deviation (SD) 176 
for continuous variables, or median and range in case of skewness, and count and percentage for 177 
categorical variables. Linear and logistic mixed-effects regression was used to compute differences 178 
in demographic characteristics of residents between countries. These models were used for the 179 
analyses because of the clustering of data (in countries and nursing homes). Country was included 180 
as a fixed effect and nursing home as a random effect in each model. We present frequencies and 181 
total numbers for all potentially inappropriate treatments in each country (Table 1).  182 
To determine differences in the prevalence between countries, we conducted logistic mixed-183 
effects regression analyses (Table 2). Country was again included as a fixed effect and nursing home 184 
as a random effect in each model. To correct for differences in demographic and clinical 185 
characteristics, we included age, length of stay, place of death, dementia at time of death, diseases 186 
(cancer, cardiovascular, pulmonary and others) and functional/cognitive status as fixed effects. 187 
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Missing values for each treatment were excluded. This allowed for a fair comparison between 188 
countries. An alpha level of p<0.05 represents statistical significance. 189 
 190 
Ethical aspects 191 
The relevant ethics committee of each country approved the study protocol (2), except for Italy 192 
and the Netherlands, where no additional ethical approval was needed since retrospective data of 193 
deceased residents was used. 194 
 195 
Results  196 
 197 
In 322 participating nursing homes, 1,707 deaths were reported. For 11 cases, no staff member 198 
could be identified (Figure 1). Of the 1,696 staff members sent a questionnaire, 1,384 responded 199 
(overall response rate 81.6%). Response rates per country are reported in the footnotes of Figure 200 
1. Sensitivity analyses using only complete cases (Table 1A in Appendix) did not result in different 201 
conclusions. 202 
 203 
Characteristics of the study sample 204 
At the time of death, mean age ranged between 81 years in Poland and 87 years in Belgium and 205 
England (Table 1). Residents were mostly female, ranging from 63.5% in Poland to 75% in England. 206 
The shortest median stay (145 days) was found in Poland, the longest (745 days) in Belgium. 207 
Residents died mainly in the nursing home (80% in Poland – 89.3% in the Netherlands). Dementia 208 
was most prevalent in Finland (82.5%) and least in England (60.2%), with between 42.9% (England) 209 
and 64% (Poland) being advanced. Severe cardiovascular disease was most often reported as the 210 
disease at time of death in all countries (34.7% in Belgium – 55.7% in Poland) except England, 211 
where this was malignant cancer (42.9%). The poorest functional and cognitive status was found 212 
in Poland (BANS-S mean score of 21.9) and the best in England (BANS-S mean score of 17.5). 213 
 214 
Differences in the prevalence of potentially inappropriate treatments in the last week of life in six 215 
countries 216 
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Use of at least one potentially inappropriate treatment in the last week ranged from 19.9% in 217 
Belgium to 68.2% in Poland (p<0.001). Artificial nutrition and/or hydration were most frequent in 218 
Poland (54.3%) and least in the Netherlands (2.7%; p<0.001). In advanced dementia use was low 219 
in England (0%), the Netherlands (1.7%), Finland (3.8%) and Belgium (4.8%) but higher in Italy 220 
(43.9%) and Poland (59.4%; not in tables), artificial fluids being used most (p<0.001), in particular 221 
in Poland (48.6%) and Italy (24.5%). Artificial enteral nutrition was administered mainly in Poland 222 
(17%; p>0.001) whereas parenteral nutrition was more prevalent in Italy (21.5%; p>0.001). Use of 223 
critical care treatments was limited, ranging from 8.7% in Poland to 1.4% in Belgium (p<0.001), 224 
with resuscitation being most frequent in England (5.5%; p=0.05) and artificial ventilation in Poland 225 
(7.1%; p>0.001). Of all treatments, antibiotics were the most commonly used in all countries, from 226 
11.3% in Belgium to 45% in Poland (p<0.001). At least one of antibiotics, antidiabetics, statins, and 227 
anticoagulants was used in 18.3% of residents in Poland and 4.8% in Belgium (p<0.001). 228 
Antidiabetic medications were administered in from 2.2% in England to 13.2% in Poland (p<0.001) 229 
and statins from 1% in Belgium to 4.4% in England (p=0.23). No use of oral anticoagulants was 230 
reported in England while in Poland use was reported for 5.5% of residents (p<0.001). Other 231 
treatments like blood transfusions, chemotherapy or radiotherapy, dialysis and surgery were rarely 232 
used, from England where no usage was reported to Poland where 3.2% of residents underwent 233 
at least one of these treatments (p<0.001). Dialysis was rarely used (p<0.001) ranging between 0% 234 
(England and Finland) and 1.6% (Poland). Surgery was performed on none of the residents in 235 
England and on up to 1.4% in the Netherlands (p<0.001). No blood transfusions were reported in 236 
England with 1% in Poland (p<0.001). Chemotherapy and radiotherapy were almost never used in 237 
the last week of life in any country, ranging from 0% in Belgium, England, the Netherlands and 238 
Poland to 1% in Italy. The risk adjustment procedure ruled out these differences being due to 239 
resident characteristics, implying they reflected differences in appropriate care between countries. 240 
Results of the complete case analysis were similar to the results from the imputed data (Table 1A 241 




Main findings 246 
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 247 
Artificial ventilation, resuscitation, blood transfusions, chemotherapy or radiotherapy, dialysis and 248 
surgery were rarely used in the last week of life of nursing home residents in most of the studied 249 
countries. However, the prevalence of most treatments differed statistically significantly between 250 
countries. Poland had the highest percentage of residents receiving at least one potentially 251 
inappropriate treatment in the last week of life. Artificial nutrition and/or hydration were common 252 
in Poland and Italy, in particular the administration of artificial fluids, even in residents with 253 
advanced dementia. Antibiotics were frequently administered in all countries, albeit with the 254 
highest rates in Poland and Italy, and antidiabetics were most often administered in Poland.  255 
 256 
Strengths and limitations 257 
 258 
This study is the first to compare the use of potentially inappropriate treatments in the last week 259 
of life of nursing home residents in representative samples of nursing homes in different countries. 260 
We were able to include data on 1,384 residents from 322 nursing homes in six European countries 261 
with different healthcare systems(6) and palliative care cultures(40). The risk adjustment 262 
procedure assured that our results reflected differences in prevalence between countries and were 263 
not influenced by differences in resident characteristics. 264 
  265 
This study also has important limitations. Firstly, it is not possible to infer from survey data when a 266 
particular treatment is ‘inappropriate’. The data may lead to the assumption that, in retrospect, all 267 
treatments administered in the last week of life were inappropriate. However, death is difficult to 268 
predict(41) so at the time it was given, a treatment may not have been considered inappropriate. 269 
Nevertheless, this study compares the use of treatments on a country level and does not aim to 270 
evaluate their appropriateness on an individual level. Secondly, the data were collected from 271 
nurses rather than directly from resident files. There is a possibility of recall bias, though nurses 272 
were instructed to consult patient records where necessary. Thirdly, we did not collect information 273 
about when treatments were initiated or the clinical indications for them, which would have 274 
provided a more detailed understanding. Fourthly, we were dealing with high quantities of missing 275 
data for some treatments (up to 24%). Therefore, sensitivity analyses were conducted via 276 
regression imputation of incomplete and complete cases. These showed mainly similar results, 277 
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indicating that the missing data influence was small. Finally, when a resident died in hospital, the 278 
nursing home may not have had information on hospital treatments in the last week of life, leading 279 
to a possible underestimation. However, given that only 15% of the residents died in-hospital, the 280 
possible bias caused by this is likely to be small. 281 
 282 
What this paper adds 283 
This study showed that the prevalence of most potentially inappropriate treatments in the last 284 
week of life was low in nursing home residents in Belgium, England, Finland and the Netherlands 285 
and particularly low compared with earlier studies in the United States and Canada. For instance, 286 
up to 23% of residents with severe cognitive impairment in Canada received statins in their last 287 
week of life, and anticoagulants were used in 52% of nursing home residents with dementia. 288 
However, comparison of data is difficult when study designs and data collection are different (data 289 
from medical records and administrative databases using prospective samples)(42–45). Besides 290 
the variation in data collection and study design, differences might be explained by the North 291 
American medical culture that tends to favor more aggressive treatments for terminally ill 292 
people(46).  293 
 294 
The use of antibiotics in the last week of life was high in all countries, from one in ten in Belgium 295 
to four in ten in Poland. There is an ongoing debate on the indications for antibiotics at the end of 296 
life(47,48) and guidelines on antimicrobial stewardship in palliative care do not yet exist(48). While 297 
some researchers consider antibiotic treatment in the last days of life to be pointless(49–51), 298 
others consider it part of symptom control(52). Earlier research on the use of antibiotics in nursing 299 
homes revealed a similar prevalence at the end of life(53–58). It is challenging to predict when 300 
someone will die(41) and whether an antimicrobial treatment will have a positive effect on 301 
symptom control, which complicates the decision(47), particularly in residents with cognitive 302 
impairments for whom expressing symptoms is difficult(48). Better recognition of the terminal 303 
phase might help with these decisions. Finally, more research is needed to guide the use of 304 
antibiotics at the end of life of nursing home residents.  305 
 306 
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The low prevalences in Belgium, England and the Netherlands might be partly explained by the 307 
culture of palliative care. In those countries many nursing homes provide palliative care and have 308 
more palliative care implementation activities (6), with high regional and national activity at policy, 309 
finance, legislation and regulation levels and a longer tradition of advance care planning than in 310 
Poland and Italy, making nursing home staff more aware of the resident’s preferences at the end 311 
of life. 312 
In contrast with other countries, the prevalence of most potentially inappropriate treatments was 313 
highest in Poland and Italy, especially for enteral and parenteral administration of nutrition and 314 
artificial fluid administration, even with advanced dementia. There are several possible 315 
explanations for this. Firstly, the high rate in Italy might be related to law enforcement. In 2009, a 316 
bill was passed(59) mandating that hydration and nutrition must always be provided, and by any 317 
means, because they are considered basic support measures and fundamental to life. In Poland, 318 
artificial feeding is considered an admission criterion for nursing homes (60). Nevertheless, their 319 
appropriateness is questionable (61), especially for those with advanced dementia(15). Taking into 320 
account the relatively high numbers with advanced dementia in our sample, with the highest rates 321 
in Poland and Italy (64% and 55%), our findings are particularly striking.  322 
Secondly, care culture in these countries rarely includes advance care planning, leaving the 323 
administration or discontinuation of certain treatments undiscussed(62). This may lead to more 324 
pressure from family members to use all possible treatments(62,63). The decision about 325 
discontinuation may also cause ethical problems when there is no advance care planning in place. 326 
In addition, because of the greater taboo about death and dying in these countries, nursing home 327 
staff may not feel competent to discuss end-of-life issues with residents and family 328 
members(5,64,65). A third possible explanation may be the low level of basic knowledge of end-329 
of-life care among nursing home staff. An earlier report of the PACE study(7) showed that 330 
knowledge of the basic physical aspects of end-of-life care among nurses and care assistants in 331 
nursing homes was lowest in Poland and Italy, particularly of indications for the use of feeding 332 
tubes(7). Fourthly, GPs in Poland and Italy recognize the terminal phase less often than in Belgium, 333 
England, Finland and the Netherlands(66). Nursing home residents in Poland and Italy also least 334 
often had palliative care as their main treatment goal in the last week of life, indicating a focus on 335 
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life-sustaining treatments. This might lead to negative consequences such as more futile or invasive 336 
treatments, more ‘in bed’ time and higher healthcare costs(67). At the same time, one could argue 337 
that treatment choices also have to be culturally sensitive to be appropriate. Although ESPEN 338 
(European Society of Clinical Nutrition and Metabolism) has elaborated European nutrition 339 
recommendations(68), there are country-specific approaches to artificial nutrition, which not only 340 
depend on legislation or health care policy and organization, but also on culture. It is also plausible 341 
that a difference in prescribing habits between countries is responsible for difference in 342 
treatments. However, this was not examined in this study and should be included in future 343 
research 344 
 345 
Implications  346 
Our findings are a potential starting point for the improvement of end-of-life care treatments in 347 
nursing homes. Practices where there is more room for improvement (e.g. artificial nutrition and 348 
hydration treatments), require particular attention. Substantial country differences call for the 349 
development of guidelines to assist nursing home staff and GPs in treatment decision-making and 350 
in recognizing the terminal phase, taking into account cultural differences. Further, greater 351 
attention needs to be paid to advance care planning in nursing homes as this may help residents, 352 
relatives and caregivers to discuss goals and preferences for future care. Finally, there is a need for 353 
staff training in end-of-life care conversations and the physical aspects of end-of-life care. Our 354 
results can be used by policy and other decision-makers to develop public health policies and 355 
interventions to improve the appropriateness of end-of-life care in nursing homes and allow the 356 
exchange of good practices across national borders. 357 
 358 
Conclusion 359 
The prevalence of potentially inappropriate treatments in the last week of life of nursing home 360 
residents was low in most studied countries, except for the use of antibiotics which was common. 361 
In Italy and Poland, all treatments were more prevalent, specially the administration of artificial 362 
nutrition and fluids and antibiotics. These differences may reflect country-specific differences in 363 
legislation, care organization, culture and the knowledge and skills of nursing home staff regarding 364 
palliative care. 365 
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° staff = nurse or care assistant most involved in resident’s care 387 
Response rates per country: Belgium (85.1% (N=291/342)); England (54.2% (N=91/168)); Finland (95.1% 388 
(N=269/283)); Italy (91.7% (N=200/229)); the Netherlands (67.5% (N=222/329)); Poland 87.4% (N=311/356). 389 
 390 
. 391 
Deaths of residents from 







Response rate: 81,6% 
No Staff member could 
be identified  
n=11 residents 
No questionnaire received 
from Staff   
n=312 residents 
Study population n=1384 
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Table 1: Demographic and clinical characteristics of deceased residents for whom an assessment by staff° was made in six countries: (N=1384) 














Age – years || 
















Female Count (%) 





















Length of stay || 















Place of Death ||^ 
Nursing home Count (%) 





















Dementia at time of death (yes) †‡ § 
Count (%) 183 (62.9) 53 (60.2) 222 (82.5) 154 (77.0) 135 (61.4) 207 (67.9) <0.001 
Advanced dementia  
Count % 83 (52.5) 18 (42.9) 78 (43.8) 66 (55.0) 60 (46.2) 96 (64.0) 0.676 
















Severe cardiovascular disease‡ 67 (34.7) 2 (9.5) 79 (37.4) 71 (47.0) 45 (30.8) 141 (55.7) <0.05 
Cerebrovascular accident (CVA)‡ 40 (20.7) 3 (14.3) 49 (23.2) 34 (22.5) 25 (17.1) 70 (27.7) 0.483 
Severe pulmonary disease‡ 33 (17.1) 3 (14.3) 17 (8.1) 40 (26.5) 17 (11.6) 18 (7.1) <0.001 
Severe neurological disease (not 
dementia) ‡  15 (7.8) 0 (0.0) 26 (12.3) 18 (11.9) 11 (7.5) 32 (12.6) 0.381 
Severe renal disease‡ 19 (9.8) 2 (9.5) 13 (6.2) 22 (14.6) 19 (13.0) 29 (11.5) 0.420 
Severe diabetes‡ 11 (5.7) 1 (4.8) 16 (7.6) 18 (11.9) 17 (11.6) 33 (13.0) 0.177 
Other severe disease‡ 31 (16.1) 3 (14.3) 51 (24.2) 33 (21.9) 4 (2.7) 33 (13.0) <0.001 
Functional/cognitive status one month 
















* Generalized linear mixed model reporting p-value for differences between countries, α =0.05 
|| Reported by administrator/manager of nursing home. For 44 out of 1,384 residents no questionnaire was returned by the administrator/manager of care home; these are 
not included as missing values reported below.  
† Reported by staff member (nurse/care assistant) most involved in care. 
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‡ Reported by general practitioner (GP). For 397 out of 1,384 residents no questionnaire was returned by the GP, these are not included as missing values below. 
§ When either the physician or the nurse (or both) considered the resident to have dementia, this was coded as yes. 
° staff = nurse or care assistant most involved in resident’s care 
^Other categories: facility hospice/ PC unit or other  
¶ Scores on BANS-S range from 7 to 28; higher scores indicate greater severity. 
Percentages may not always add up to 100 because of rounding. 
Abbreviations: BANS-S = Bedford Alzheimer Nursing Severity Scale, SD = Standard Deviation 
Missing values: age=13, sex=13, size=60, length of stay=36, place of death=11, dementia =11, stage of dementia=187 (419 not applicable because resident did not have 




































Artificial nutrition and hydration treatments         












(17%) 0.7% - 17% <0.001 












(12.9%) 0.0% - 21.5%  <0.001 












(48.6%) 2.3% - 48.6% <0.001 













(54.3%) 2.7% - 54.3% <0.001 


























(7.1%) 1% - 7.1% <0.001 












(8.7%) 1.4% - 8.7% <0.001 
Antimicrobial treatment          












(45%) 11.3% - 45% <0.001 







































(5.5%) 0.0% - 5.5% <0.001 












(18.3%) 4.8% - 18.3% <0.001 







































(1.6%) 0.0% - 1.6% <0.001 
Surgery 1  0  1  1  3 2  0.0% - 1.4% <0.001 
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Generalized linear mixed model reporting p-value for differences between countries, α =0.05 
All treatments are reported by staff member (nurse/care assistant) most involved in care. 
°Results from regression imputation. 
* To correct for differences in demographic and clinical characteristics, we included age, length of stay, place of death, dementia at time of death, diseases at time of death 
(cancer, cardiovascular, pulmonary and other diseases) and functional/cognitive status as fixed effects.  
 
(0.3%) (0.0%) (0.4%) (0.5%) (1.4%) (0.6%) 












(3.2%) 0.0% - 3.5% <0.001 












(68.2%) 19.9% - 68.2% <0.001 
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Artificial nutrition and hydration treatments         












(24.9%) 0.7% - 24.9% <0.001 












(19.8%) 0.0% - 19.8%  <0.001 












(52.1%) 6% - 52.1% <0.001 













(66.3%) 2.9% - 66.3% <0.001 


























(11.8%) 1.1% - 11.8% <0.001 












(14.8%) 1.5% - 14.8% <0.001 
Antimicrobial treatment          












(44.2%) 12% - 44.2% <0.001 







































(9.6%) 0.0% - 9.6% <0.001 












(31%) 5.8% - 31% <0.001 


























(0.0%) 0.0% - 1.3% 0.07 
Dialysis 1  0  0  2  1  5  0.0% - 2.9% <0.001 
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Generalized linear mixed model reporting p-value for differences between countries, α =0.05 
All treatments are reported by staff member (nurse/care assistant) most involved in care. 
* To correct for differences in demographic and clinical characteristics, we included age, length of stay, place of death, dementia at time of death, diseases at time of death 
(cancer, cardiovascular, pulmonary and other diseases) and functional/cognitive status as fixed effects.  
Percentages may not correspond with count due to missing values. 
Missing values for each treatment: enteral administration: 214, parenteral administration: 233, artificial fluid: 194, resuscitation: 272, ventilation: 261, antibiotics: 146, 
statins: 328, antidiabetics: 274, anticoagulants: 317, blood transfusion: 274, chemotherapy/radiotherapy: 278, dialysis: 285, surgery: 329  
 













(1.3%) 0.0% - 1.5% <0.001 












(6.5%) 0.0% - 6.5% <0.001 
